<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908089</url>
  </required_header>
  <id_info>
    <org_study_id>NEO-RACo</org_study_id>
    <nct_id>NCT00908089</nct_id>
  </id_info>
  <brief_title>TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis</brief_title>
  <acronym>NEO-RACo</acronym>
  <official_title>Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seinajoki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jyväskylä Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rheumatism Foundation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orton Invalid Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Carelia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lappi Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital of Kanta-Hame</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FIN-RACo trial is an investigator initiated multicenter (n=15 centers in Finland)
      prospective study on the treatment of patients with early rheumatoid arthritis (RA) with
      combination therapy with disease modifying antirheumatic drugs starting with methotrexate,
      sulphasalazine, hydroxychloroquine and prednisolone (COMBI). During the first 6 months, the
      patients are randomized to treatment with infliximab/placebo added on the combination
      treatment. The study is prospective for 5 years, with extension to 10 years. The target is to
      induce remission in both treatment arms. To reach this target, the investigators use frequent
      changes of doses and anti-rheumatic drugs and use of intra-articular glucocorticoid
      injections. The primary endpoints are the proportions of patients with remission at 2 and 5
      years in both treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We want to study, whether early treatment with infliximab for 6 months started parallel with
      the combination therapy of methotrexate, sulphasalazine, hydroxychloroquine and prednisolone
      (COMBI) can induce quick remission in patients with early RA, if the remission can be
      sustained after 6 months on patients continuing the COMBI treatment and can diminish the risk
      of progression of erosive changes in patients with early RA, and if we can reduce costs of
      the 2 treatment arms with respect to costs due to the disease.

      100 patients with early RA will be included in the study. The patients are randomised into
      COMBI + placebo or into COMBI +infliximab.

      All patients are treated openly with COMBI, starting with a combination of methotrexate,
      sulfasalazine, hydroxychloroquine and prednisolone. In addition, the patients are randomized
      into a) infliximab or b) similar placebo. The COMBI treatment will be continued for 2 years,
      but the infliximab/placebo will be given only during the first 6 months. After 2 years, if
      the patient is in remission, the prednisolone will be gradually tapered off. If the patient
      is still in remission, the conventional DMARDs can be sequentially tapered down. If the
      remission is lost, the last DMARD is reinstituted. If the patient is not in remission of
      COMBI, after 26 weeks, treatments are free, including the institution of a biological drug.

      The patients will be evaluated clinically at week 0, 4, 6, 10, 14, 18, 22 and 26 (at the day
      of infusion, prior to the infusion) and at months 8, 10, 12, 15, 18, 21, and 24 and at
      annually thereafter till 10 years.

      If a patient has adverse events due to individual drugs in the COMBI, the treatment can be
      substituted by another DMARD.The disease activity will be measured according to the ACR core
      set of disease activity.

      Radiology of hands (PA projection) and feet (PA projection) at baseline and at 1, 2, 3, 4, 5,
      7 and 10 years. We also will record adverse events, sick leaves, loss of income, costs, and
      work disability.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission by ACR criteria</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiology (erosions)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained remission</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with sustained ACR remission from month 3 till the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>2</time_frame>
    <description>Cumulative direct and indirect costs at 2 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HAQ</measure>
    <time_frame>1, 2, 3, 4 and 5 years</time_frame>
    <description>Health assessment questionnaire(HAQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Work disability</measure>
    <time_frame>2, 3, 4 and 5 years</time_frame>
    <description>Permanent work disability</description>
  </other_outcome>
  <other_outcome>
    <measure>Good response</measure>
    <time_frame>5 years</time_frame>
    <description>Number of patients with sustained good response (&gt;=ACR50%) from month 3 till the end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of arthroplasties</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative number of arthroplasties at 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Direct and indirect costs</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative direct an indirect costs at 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>10 years</time_frame>
    <description>Monitoring of safety and adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>ACR Remission</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>DAS28 remission</measure>
    <time_frame>2, 3, 4, 5, 7 and10 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HAQ</measure>
    <time_frame>10 years</time_frame>
    <description>Health assessment questionnaire (HAQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Work disability</measure>
    <time_frame>10 years</time_frame>
    <description>Cumulative permanent work disability up till 10 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of arthroplasties</measure>
    <time_frame>10 years</time_frame>
    <description>Cumualite number of arthroplasties by 10 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Direct and indirect costs</measure>
    <time_frame>10 years</time_frame>
    <description>Cumulative direct and indirect costs by 10 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiology (erosions)</measure>
    <time_frame>10 years</time_frame>
    <description>radiologic changes in hands and feet</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab</intervention_name>
    <description>methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months</description>
    <arm_group_label>Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab</arm_group_label>
    <other_name>Trexan, Salazopyrin, Oxiklorin, Prednison, Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo</intervention_name>
    <description>methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months</description>
    <arm_group_label>Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo</arm_group_label>
    <other_name>Trexan, Salazopyrin, Oxiklorin, Prednison, 0.9% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA fulfilling the ACR classification criteria for RA

          -  Patients within age group of 18-60 years

          -  Patients not permanently work disabled or retired

          -  Duration of symptoms &lt; 12 months, and who have not received DMARD previously

          -  Patients with active disease (see below)

          -  Criteria for active disease at entry:

               -  &gt; 6 swollen joints (66 joint count)

               -  &gt; 6 tender joints (68 joint count)

               -  duration of early morning stiffness &gt; 45 min and/or ESR &gt; 30 mm/h and/or CRP &gt; 20
                  mg/l

        Exclusion Criteria:

          -  Previous treatment with DMARDs

          -  Previous treatment with oral glucocorticoids during the previous 6 months

          -  Less than 30 days from previous intra-articular injection with corticosteroids

          -  Allergy to sulphonamides

          -  Allergy to acetylsalicylic acid

          -  Allergy to methotrexate

          -  Allergy to antimalarials

          -  Previous treatment with biologicals

          -  Serum creatinine value &gt; upper limit of normal (registered in 2 different blood
             samples)

          -  Serum transaminase levels &gt; 2x upper limit of normal (registered in 2 different
             samples)

          -  Known/previous malignancy excluding basalioma or in situ cervical cancer &gt;5 years
             previously

          -  Cardiac failure (NYHA III-IV)

          -  Previous history of tuberculosis and/or exposition to tuberculosis and/or typical
             changes of previous/active tuberculosis in chest radiology

          -  Active infection

          -  Pregnancy

          -  Leukopenia (WBC &lt; 4 x 109/l)

          -  Thrombocytopenia (platelets &lt; 100 x 109/l)

          -  Active peptic ulcer

          -  Type I or type II diabetes under poor control

          -  Heavy use of alcohol

          -  Fertile women not practising contraception or who are planning pregnancy

          -  Male patients wishing to have children during the therapy

          -  Other autoimmune rheumatic disease

          -  Other chronic disease which judged by the physician could influence the patient's
             compliance or intervene the study course

          -  Patient is not cooperative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjatta Leirisalo-Repo, MD, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timo Möttönen, MD, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markku Korpela, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riitta Luosujärvi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oili Kaipiainen-Seppänen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markku Kauppi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatism Foundation Hospital</name>
      <address>
        <city>Heinola</city>
        <zip>FI-18120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orton Invalid Foundation Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00280</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämeenlinna Central Hospital</name>
      <address>
        <city>Hämeenlinna</city>
        <zip>FI-13530</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jyväskylä Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <zip>FI-40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-703211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lappeenranta Central Hospital</name>
      <address>
        <city>Lappeenranta</city>
        <zip>FI-53130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Rauma</city>
        <zip>FI-26100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rovaniemi Central Hospital</name>
      <address>
        <city>Rovaniemi</city>
        <zip>FI-96100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <zip>FI-60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FI-21540</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <results_reference>
    <citation>Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.</citation>
    <PMID>22753402</PMID>
  </results_reference>
  <results_reference>
    <citation>Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.</citation>
    <PMID>25274892</PMID>
  </results_reference>
  <results_reference>
    <citation>Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.</citation>
    <PMID>23908187</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Marjatta Leirisalo-Repo</investigator_full_name>
    <investigator_title>MD, PhD, Prof</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>methotrexate</keyword>
  <keyword>sulfasalazine</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

